Canopy Growth (CGC)
(Delayed Data from NSDQ)
$4.86 USD
+0.27 (5.88%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.86 USD
+0.27 (5.88%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.
Clover Health (CLOV) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $13.01, marking a +1.76% move from the previous day.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.
Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect gains from strategic deals.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Baxter (BAX) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
What's in Store for West Pharmaceutical's (WST) Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.
Canopy Growth Corporation (CGC) Moves 8.6% Higher: Will This Strength Last?
by Zacks Equity Research
Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 27.78% and 3.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $18.80, marking a -0.58% move from the previous day.
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cannabis Giant Tilray (TLRY) Skyrocketed Today
by Madeleine Johnson
Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $23.91, moving -0.87% from the previous trading session.
Forget Meme Stocks: Buy These Strong Growth Stocks with Big Upside
by Benjamin Rains
Investors might want to consider adding growth focused stocks to their portfolios that are still trading below their highs, even as the meme stocks soar once again...
Company News for Jun 2, 2021
by Zacks Equity Research
Companies In The News Are: ABT, CLDR, KKR, CGC, NIO.